Guimarães Milena Maria Moreira, de Oliveira Antônio Ribeiro, Penido Mariana Guimarães, Queiroz Leonardo Campos, Goulart Eugênio Marcos Andrade, Greco Dirceu Bartolomeu, Machado Lucas José de Campos
Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brasil.
Ann Nutr Metab. 2007;51(1):35-41. doi: 10.1159/000100819. Epub 2007 Mar 14.
To compare the intra-abdominal fat thickness measured by ultrasound between HIV-infected patients treated or not with antiretroviral drugs and to correlate these visceral adiposity measurements to other parameters of cardiovascular risks.
In a transversal observational study, 160 HIV-infected patients were recruited and divided in two groups, i.e., 123 antiretroviral (ARV)-treated and 37 ARV-naïve patients. These patients were submitted to anthropometric determinations, laboratorial analysis, ultrasonographic measurements of subcutaneous and intra- abdominal fat thickness and to tetrapolar bioelectrical impedance analysis in order to measure the body composition.
In the patients treated with highly active antiretroviral therapy (HAART) the intra-abdominal fat pad was significantly thicker than that of the untreated group (69 +/- 21 mm, n = 123 vs. 60 +/- 18 mm, n = 37; p = 0.03 Student's t test). The intra-abdominal fat thickness correlated significantly with plasma triglyceride, total cholesterol, fasting glucose, glucose measurements 2 h after dextrose load, fasting insulin, HOMA-IR index, systolic and diastolic blood pressures, weight, BMI, WHR and caliper-measured total fat percentage.
The results showed that antiretroviral therapy is associated with increased ultrasonographic measurements of visceral adiposity. Our data demonstrated a strong correlation between intra-abdominal fat thickness and independent risk factors of cardiovascular disease: atherogenic lipid profile and insulin resistance.
比较接受或未接受抗逆转录病毒药物治疗的HIV感染患者通过超声测量的腹内脂肪厚度，并将这些内脏脂肪测量值与心血管风险的其他参数进行关联。
在一项横向观察性研究中，招募了160名HIV感染患者并将其分为两组，即123名接受抗逆转录病毒（ARV）治疗的患者和37名未接受ARV治疗的患者。这些患者接受了人体测量、实验室分析、皮下和腹内脂肪厚度的超声测量以及四极生物电阻抗分析，以测量身体成分。
在接受高效抗逆转录病毒治疗（HAART）的患者中，腹内脂肪垫明显比未治疗组厚（69±21毫米，n = 123 vs. 60±18毫米，n = 37；p = 0.03，学生t检验）。腹内脂肪厚度与血浆甘油三酯、总胆固醇、空腹血糖、葡萄糖负荷后2小时的血糖测量值、空腹胰岛素、HOMA-IR指数、收缩压和舒张压、体重、BMI、腰臀比以及卡尺测量的总脂肪百分比显著相关。
结果表明，抗逆转录病毒治疗与内脏脂肪超声测量值增加有关。我们的数据表明腹内脂肪厚度与心血管疾病的独立危险因素之间存在密切关联：动脉粥样硬化性脂质谱和胰岛素抵抗。
